Select publications

Blackhall FH et al. Erlotinib in non-small cell lung cancer: A review. Expert Opin Pharmacother 2005;6(6):995-1002. Abstract

Byrne BJ, Garst J. Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Curr Oncol Rep 2005;7(4):241-7. Abstract

Di Maio M et al. Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Cell Physiol 2005;[Epub ahead of print]. Abstract

Gray R et al. The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: The Eastern Cooperative Oncology Group’s (ECOG) experience with bevacizumab (anti-VEGF). Proc ASCO 2003;Abstract 825.

Hanna NH et al. Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). Proc ASCO 2005;Abstract LBA7004.

Herbst RS et al. Phase I/II Trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23(11):2544-55. Abstract

Johnson DH et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-91. Abstract

Noda K et al; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346(2):85-91. Abstract

Sandler AB et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Presentation. ASCO 2005;Abstract LBA4.

Shigematsu H et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97(5):339-46. Abstract